Clinical Trial

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in healthy population aged 9-17 years old in comparison with aged 18-26.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-09-23; most recent amendment 2025-07-16.
Status change: Not Yet Recruiting → Active, Not Recruiting 2021-10-02
Trial Details
NCT Number NCT05056402
Lead Sponsor Xiamen University
Collaborators: Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Conditions Cervical Cancer, Condylomata Acuminata
Enrollment 1,382 participants
Start Date 2021-09-19
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-22